Overview of Rudakol

Quick Facts

Property	Description
Active ingredient	Mebeverine hydrochloride
Form	Film-coated tablets, Modified release capsules
Pharmacological class	Musculotropic Antispasmodic
General purpose	Relief of smooth muscle spasms in the gut
Origin	Synthetic organic compound

What is Rudakol and Its Classification?

Rudakol is a pharmaceutical preparation whose sole active ingredient is Mebeverine hydrochloride, the key substance responsible for the medicine's effect. This drug is classified pharmacologically as a musculotropic antispasmodic, distinguishing it from agents that primarily act through the nervous system. Mebeverine is a synthetic organic compound structurally developed as an analog of papaverine, specifically engineered for focused action. Rudakol's identity as a single-entity antispasmodic is clinically recognized for its targeted efficacy in addressing painful muscle hyperactivity in the gastrointestinal tract.

Rudakol's Physical Form and Composition

Rudakol is formulated for oral use and is typically supplied as solid preparations, generally available as film-coated tablets or modified release capsules. The presence of modified release capsules is a key differentiating feature, as this design ensures a gradual, sustained release of the active Mebeverine hydrochloride over an extended period. The solid composition includes the active ingredient combined with foundational solid excipients, such as fillers like lactose monohydrate in certain tablet formulations. This design supports a consistent therapeutic effect in the gut. Mebeverine is globally recognized for its localized muscle relaxant properties.

General Purpose: A Focused Approach to Spasm Relief

The general purpose of Rudakol is to provide symptomatic relief by reducing the painful, involuntary contractions, or spasms, in the gut wall. The medicine functions by inducing a direct, non-specific relaxation of the intestinal smooth muscles, where its effect is localized. This action helps to restore a more comfortable muscular state, alleviating the painful cramping associated with functional bowel disturbances. Clinical data supports the efficacy of Mebeverine in improving overall relief of abdominal discomfort associated with gut hypermotility. This spasmolytic activity provides a focused, non-systemic approach to muscle relaxation in the gut.

What side effects are possible with Rudakol?

Possible side effects and safety information

The safety profile for mebeverine hydrochloride (Rudakol) is officially classified by regulatory authorities based on System-Organ Classes (SOCs) and adverse reaction frequency tiers. The overall incidence of reactions is generally recognized as being low, with the most commonly classified effects considered uncommon.

Official Adverse Reactions and System Classification

Adverse reactions documented in official labeling are grouped primarily across several physiological systems. The majority of documented effects are associated with Skin and Subcutaneous Tissue disorders and the Immune System.

Uncommon Reactions: The most frequently observed reactions are dermatological, including rash and urticaria (hives).
Serious Adverse Reactions: While rare, clinically important reactions are manifestations of severe hypersensitivity phenomena. These include anaphylactic reactions, angioedema (swelling beneath the skin), and facial edema, which are the most severe systemic allergic responses documented in regulatory texts.

Administration-Agnostic Safety Constraints

The official labeling defines specific restrictions and populations where the medicine should be avoided.

Constraint Type	Official Regulatory Statement
Absolute Contraindication	Strictly contraindicated in patients with known or suspected paralytic ileus (intestinal paralysis), as noted in labeling across international jurisdictions.
Population-Specific Note	The medicine is not recommended for use in children under 18 years of age in some jurisdictions due to insufficient safety and efficacy data.
High-Risk Groups	Not recommended during pregnancy or breast-feeding due to limited clinical safety data.

These statements structure the safety profile by defining the risk spectrum—from uncommon skin reactions to rare, serious allergic events—and establishing non-negotiable limitations on use based on specific patient conditions and age groups.

Overdose and Emergency Response

Rudakol Overdose and When to Seek Help

Overdose Manifestations and Severity

Feature	Regulatory Documentation
Documented Presentations	Symptoms are reported as generally mild or absent and typically rapidly reversible.
Physiological Systems Affected	Observed manifestations are of a neurological and cardiovascular nature. CNS excitability is noted as a theoretical possibility in official prescribing information.

Emergency Action and Management

Feature	Official Regulatory Statement
Urgent Help Required	Seek immediate medical attention or go to a hospital straight away if an overdose is suspected.
Antidote Status	No specific antidote is known for this overdose.
Management	Symptomatic treatment is recommended. Patients’ vital functions should be monitored closely.
Procedural Interventions	Gastric lavage should only be considered in cases of multiple intoxication or within the first one hour of ingestion. Absorption reducing measures are not necessary in most cases.

The regulatory profile thus defines the event by its generally mild presentation and the mandated reliance on symptomatic support and close monitoring, as no specific reversal agent exists. The official guidelines emphasize the necessity to contact emergency services immediately upon suspicion of overdose.

Therapeutic Uses of Rudakol

What Rudakol Treats: Main Uses and Benefits

Rudakol is applied across domains where additional symptomatic support is needed, relevant to symptoms related to heightened physiological activity. This medication is commonly used across conditions characterized by periods of heightened symptoms and in situations involving recurrent or episodic manifestations.

It is often used during phases when symptoms become more noticeable and when short-term assistance is needed to help patients cope more steadily with difficult episodes. It is relevant for managing symptoms that interfere with daily comfort, such as clusters that may become intense or disruptive, especially those creating noticeable physiological strain. The medication is considered a supportive option when symptoms interfere with routine activities.

“This medication is applied in addressing symptoms related to acute changes, supporting general well-being during symptomatic phases.”

Quick Fact: Support for Symptomatic Phases

Rudakol helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms escalate temporarily.

Regulatory References

HALMED medicinal product database entry

Eligibility and Restrictions for Use

Population Eligibility for Rudakol

Rudakol (Mebeverine hydrochloride) eligibility is defined by regulatory authorities based on age, specific medical conditions, and physiological status.

Populations Approved and Not Recommended

Status	Population Group
Approved Use	Adults, including the elderly, under standard labeled conditions.
Not Recommended	Children and adolescents below 18 years of age.

Use in the paediatric population is not recommended because official regulatory documents indicate there is insufficient data available to establish safety and efficacy in individuals under 18. For older adults, use is established, and no specific dosage adjustment is deemed necessary based on available regulatory post-marketing data.

Absolute Contraindications

Rudakol is formally contraindicated and must not be used in individuals with known hypersensitivity to the active substance, Mebeverine hydrochloride, or to any of the non-active excipients in the formulation. Contraindication also extends to patients with certain hereditary sugar intolerances, such as the Lapp lactase deficiency or glucose-galactose malabsorption, due to the presence of lactose excipients in the tablet form.

Physiological Restrictions

Use during pregnancy is not recommended as data is limited. Furthermore, the medicine should not be used by women who are breastfeeding, as it is unknown whether the active substance or its metabolites are excreted in human milk. Patients with renal or hepatic impairment do not typically require a dosage adjustment, as regulatory sources have identified no specific risk for these groups.

What should I know about interactions with other medicines?

Rudakol Interactions with other medicines and products

The official regulatory profile for Rudakol (Mebeverine hydrochloride) is defined by a general absence of documented interactions with other medicinal products.

Interaction Scope	Official Regulatory Finding
Medicinal product categories with documented interactions	None. Regulatory documents state no dedicated interaction studies have been performed with other medicines.
Specific interacting medicines (if explicitly listed)	None. No specific medicinal products are listed as interacting substances in the official label.
Mechanistic basis of interactions	None documented. No specific pharmacokinetic (e.g., CYP enzymes, transporters) or pharmacodynamic interaction mechanisms with other medicines are described in the regulatory text.
Timing-based interaction rules	None documented. No mandatory separation of administration time is required for co-administered medicinal products.
Interacting Substances (Non-Medicine)	Alcohol (Ethanol): Formal studies demonstrated the absence of any interaction with mebeverine hydrochloride.
Population-specific interaction notes	Elderly, Renal, and/or Hepatic Impairment: No specific interaction risk could be identified from available post-marketing data for these patient groups.

Interaction Classifications (High-Level)

Classification	Official Regulatory Finding
Interaction severity classification	Unclassified/None. No clinically significant interactions are classified in the official label.
Regulatory basis	Summary of Product Characteristics (SmPC) / National health agency prescribing information.
Interaction-context constraints	The official profile is defined by the documented absence of known interactions with co-administered medicinal products.

Resulting Interaction Structure

Official interaction statements:

The official prescribing information states that dedicated interaction studies with other medicinal products have not been performed.
A specific study addressing interaction with alcohol (ethanol) demonstrated the absence of any interaction with mebeverine hydrochloride.
No specific risk regarding drug interactions has been identified from post-marketing data for patients with renal or hepatic impairment, or for the elderly population.

Connection to the overall interaction profile: The regulatory interaction structure for Rudakol is primarily defined by the documented absence of drug–drug interactions, based on the statement in official labeling that dedicated interaction studies were not conducted for other medicines. Consequently, the label does not list mandatory timing rules, specific contraindications, or metabolic interaction warnings related to co-administered drugs, outside of confirming the lack of interaction with alcohol.

Mechanism of Action

How Rudakol Works

Rudakol initiates its effect by acting as a selective modulator on defined cell surface receptors, which are components of central or peripheral regulatory systems. This precise binding either activates or blocks these receptors, thereby directly adjusting the cell's immediate response to its own endogenous signaling molecules.

Following receptor engagement, Rudakol's action propagates through the cell by influencing associated intracellular signal transduction cascades. By modifying these early molecular steps, the drug is used to modulate the flow of information in systems characterized by heightened pathway activation, resulting in an adjusted internal cellular signaling state.

This overall mechanism functions to modulate activity in overactive or dysregulated physiological processes within the targeted systems. This intervention limits the impact of excessive mediator activity, which results in altered physiological responses that shape the defined system-level consequences.

Dosage and Administration Information

Rudakol (Mebeverine hydrochloride) is administered exclusively via the oral route, available as 135 mg film-coated tablets or 200 mg modified-release capsules, with each formulation prescribing a distinct schedule. The standard administration protocol for both forms requires that the dose be taken preferably 20 minutes before meals. The tablets and capsules must be swallowed whole with an adequate amount of water; specifically, the modified-release capsules must not be crushed or chewed to preserve the sustained-release mechanism.

Formulation	Standard Adult Dosing	Frequency
135 mg Tablets	One 135 mg tablet per dose.	Three times daily
200 mg Capsules	One 200 mg capsule per dose.	Twice daily

The treatment duration is not limited and may be continued as long as necessary; however, the dosage can be gradually reduced once control has been established. Regarding specific populations, the medicine is not recommended for use in adolescents and children below 18 years due to limited data. No specific dose adjustment is considered necessary for older adults or for patients with established hepatic or renal impairment. If a scheduled dose is missed, the patient should continue with the next dose at the usual time and not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rudakol

Evidence for Use in Irritable Bowel Syndrome (IBS)

The research base for Rudakol (Mebeverine) primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews that have studied the compound in adult populations characterized by Irritable Bowel Syndrome (IBS) symptoms. These studies included patients across all major IBS subtypes, which are conditions characterized by fluctuating or episodic manifestations in the gut.

Researchers monitored patient-reported outcomes describing perceived discomfort, such as abdominal pain intensity and overall global assessment of symptom change. Trials were typically conducted over short-term observation periods, generally lasting from a few weeks up to 12 weeks. Findings related to the measurement of changes in the specific symptom of abdominal pain have been described in some studies. However, pooled data from several meta-analyses often suggest that the overall findings regarding the global assessment of symptom change compared to a placebo were mixed and heterogeneous, meaning the results varied widely across the studies.

Evidence in Functional Abdominal Pain – Not Otherwise Specified (FAP-NOS)

Research exploring the use of Rudakol in adolescents and children with functional abdominal pain disorders, such as FAP-NOS, is limited. The available evidence for this specific group comes from only a small number of dedicated Randomised Controlled Trials. These studies examined outcomes related to treatment success, often defined as a specified reduction in abdominal pain intensity and frequency.

In these trials, which generally had a short-term follow-up duration of around eight weeks, findings describe patterns observed in the studies but did not consistently distinguish between the active compound and placebo when assessing treatment success or adequate symptom relief. This indicates that the data for certain groups remain insufficient, and certainty remains low for this population.

Long-Term Research and Durability of Response

Most core clinical evaluations of Rudakol have focused on establishing patterns of response over defined time intervals, typically during short-term treatment phases lasting only a few months. For this reason, the long-term effects are not fully established. The evidence currently available provides limited information for long-term outcomes or the durability of the symptom patterns observed beyond the initial study periods.

What is Still Uncertain About Rudakol's Research Base

The scientific literature highlights several areas where the research evidence for Rudakol remains uncertain. One key limitation is the methodological heterogeneity noted in some systematic reviews. Furthermore, comparative evidence is lacking in some areas, particularly in head-to-head comparisons against all newer antispasmodic agents. The findings describe group patterns, not personal outcomes, and the research highlights what is known—and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Rudakol (FAQ)

Q: How quickly does Rudakol start to work?

According to official product information, for the immediate-release tablet form, the effects of Rudakol are expected to begin after approximately one hour. It is important to remember that individual patient response times may vary.

Q: How long do the effects of Rudakol last?

The duration of action depends on the specific formulation being used. For the modified-release capsules, which are designed for prolonged action, the active substance is released over an extended period, generally cited in regulatory texts as 8 to 12 hours.

Q: Is it okay to take Rudakol if I am fasting?

Regulatory guidance states that the medicine is typically taken, swallowed whole with water, preferably 20 minutes before a meal. This timing is specified in the official product instructions.

Q: Does Rudakol cause weight gain or weight loss?

Official prescribing documents do not list changes in body weight, such as weight gain or weight loss, as known side effects of Rudakol. The full list of known adverse effects is available in the possible side effects section of the medicine’s official label.

Q: Is feeling tired a common side effect of Rudakol?

Official product information indicates that tiredness, or a general feeling of malaise, has been reported as an adverse effect. However, the most commonly classified reactions in official documents are dermatological (skin related).

Q: Is Rudakol classified as an opioid or controlled substance?

Rudakol is classified pharmacologically as a musculotropic antispasmodic, meaning it acts directly on the muscles in the gut wall. It is not classified as an opioid, nor is it listed as a controlled substance by regulatory authorities.

Q: Does Rudakol affect the results of blood tests?

Some prescribing information mentions that the active ingredient, mebeverine, has been reported to cause an unexpected finding in certain diagnostic tests. Specifically, it may result in a false positive result for amphetamines in a urine drug-screening test.

Q: Is there any risk of becoming dependent on Rudakol?

The medicine is known to act primarily locally in the gut and is not typically associated with effects on the central nervous system (CNS). Official regulatory documents do not list dependency as a known side effect or risk associated with its use.

Q: Is it normal to feel a change in appetite while taking Rudakol?

Official product information lists a loss of appetite as one of the reported adverse effects. Patients who experience any changes in appetite or other concerning effects are generally advised to discuss this with a healthcare provider.

Q: Has Rudakol been on the market for a long time?

The active ingredient in Rudakol, mebeverine, has been in use for several decades. Official records indicate that the substance was first registered as early as 1965.

Q: Is Rudakol a non-steroidal anti-inflammatory drug (NSAID)?

No, Rudakol is not classified as a non-steroidal anti-inflammatory drug (NSAID). Its pharmacological classification is that of a musculotropic antispasmodic, meaning its function is to provide direct relief for smooth muscle spasms in the gut.

Q: Does Rudakol contain any lactose or gluten?

According to the formulation details in official documents, the tablets contain lactose monohydrate as a non-active ingredient (excipient). It is important to note that the official prescribing documents do not list gluten as a component.

Q: Why do official documents say Rudakol has a 'Boxed Warning'?

Official prescribing information for the active substance mebeverine hydrochloride does not contain a Boxed Warning (sometimes called a Black Triangle Warning). The most serious warnings in the regulatory text relate to rare, severe allergic reactions.

Q: Who manufactures Rudakol?

The active ingredient, mebeverine hydrochloride, is produced by a number of pharmaceutical companies. The medicine is sold globally under various brand names, with manufacturing and license holders differing by country and specific product formulation.

Q: Do I need a special prescription to get Rudakol?

Depending on the country and specific formulation, Rudakol may be categorized differently. In some jurisdictions, it is available by prescription only, while in others, it may be purchased directly from a pharmacist following a diagnosis of Irritable Bowel Syndrome (IBS).

Q: Will Rudakol still work if I take it with food?

Official instructions advise taking the medicine preferably 20 minutes before a meal. This timing is specified in official documents to support the intended use.

Q: How is the safety of Rudakol monitored after it is approved?

Drug safety is monitored continuously through a process called pharmacovigilance, which involves collecting reports of adverse effects. Official documents instruct users to report any experienced side effects to a doctor or pharmacist.

Q: Are there any restrictions on driving or operating machinery while taking Rudakol?

According to the official patient information, Rudakol is not likely to affect your ability to safely drive or operate tools or machinery.

Q: Does Rudakol affect sleep patterns?

Official product safety information indicates that insomnia, or difficulty sleeping, has been reported as an adverse effect in some patient reports.

Q: What is the difference between Rudakol and its generic version?

Rudakol is a brand name used for the medicine whose active ingredient is mebeverine hydrochloride. This active ingredient is also available through various manufacturers as a generic medicine.

Q: What should I do if a side effect is listed as 'rare'?

Official patient safety instructions state that if any side effect is experienced, patients are advised to communicate this with a healthcare professional. For any severe allergic reaction or sudden, serious symptom, official guidance recommends seeking medical attention immediately.

Q: Do I have to keep taking Rudakol forever, or can I stop when I feel better?

Official regulatory documents specify that discontinuing use, even when symptoms improve, should occur only under the guidance of a healthcare professional. The treatment duration is not limited and may be continued as long as necessary.

Q: Does Rudakol contain any stimulants?

Rudakol is classified as an antispasmodic designed for action in the gut, and it is not typically associated with effects on the central nervous system (CNS). Stimulants are not listed among the active or non-active ingredients in the official product information.

How should Rudakol be stored and disposed of?

How to Store and Dispose of Rudakol (Mebeverine Hydrochloride)

Official regulatory guidelines define specific conditions for storing Rudakol to maintain its stability.

Storage Environment: The medicine must be stored in a dry place at a temperature not greater than 30°C and must be protected from light.
Packaging Rules: Rudakol must be kept in the original container to ensure protection from moisture and light.
Stability: The medicine should not be used past the expiry date. For certain packaging, the product must be discarded 90 days after the first opening.
Child Safety: Rudakol must be kept out of the sight and reach of children.

For disposal, the product must not be thrown away via wastewater or household waste. Unused or expired medicine must be properly discarded by consulting a pharmacist for local pharmaceutical waste handling.

Rudakol